Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 916
- Registration Number
- NCT01549964
Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
- Conditions
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 337
- Registration Number
- NCT01545388
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 200
- Registration Number
- NCT01529541
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Sitagliptin Dose Determination Study
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT01530178
- Locations
- 🇺🇸
Albert Einstein College of Medicine CRC, Bronx, New York, United States
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT01519674
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT01485614
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 166
- Registration Number
- NCT01477853
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
- Conditions
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 660
- Registration Number
- NCT01462266
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-12-25
- Lead Sponsor
- Intarcia Therapeutics
- Registration Number
- NCT01455909
- Locations
- 🇺🇸
Intarcia Therapeutics, Inc, Hayward, California, United States
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 535
- Registration Number
- NCT01455870
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.